Abstracts tagged "SLE"

Abstract Number: 763 • 2016 ACR/ARHP Annual Meeting
Rituximab As a Corticosteroid-Sparing Agent in Patients with Systemic Lupus Erythematosus
Na Ri Kim¹, Jung Su Eun¹, Jong Wan Kang¹, Eon Jeong Nam¹ and Young Mo Kang², ¹Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, Republic of
Background/Purpose : The treatment of active systemic lupus erythematosus (SLE) remains problematic because the current treatment regimen based on corticosteroids and immunosuppressive agents have significant…
Abstract Number: 1053 • 2016 ACR/ARHP Annual Meeting
Evaluating the Charla De Lupus (Lupus Chat)® Program’s Teen, Young Adult and Parent Support Group: Reaching the Hispanic/Latino Community through a Family Model of Support
Melissa T. Flores¹, Jillian A. Rose², Priscilla Toral¹, Roberta Horton¹, Dariana M. Pichardo¹, Lillian Mendez¹ and Lisa F. Imundo³, ¹Social Work Programs, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY
Background/Purpose: Research shows that chronic illnesses such as SLE have multi-level impact on the family; it can be challenging for both patients & caregivers to…
Abstract Number: 1765 • 2016 ACR/ARHP Annual Meeting
Minimal Clinically Important Differences for Generic Patient Reported Outcomes Tools in SLE
Hervé Devilliers¹, Narender Annapureddy² and Meenakshi Jolly³, ¹Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ²Rheumatology and Immunology, Vanderbilt University, Nashville, TN, ³Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with Systemic lupus erythematosus (SLE) have significant impairment in quality of life (QOL). Health related QOL (HRQOL) is one of the four established…
Abstract Number: 2059 • 2016 ACR/ARHP Annual Meeting
Serine/Arginine-Rich Splicing Factor 1 (SRSF1) Is a Novel Factor in T Cell Homeostasis and Its Selective Loss in T Cells Causes Autoimmunity and Lupus-like Nephritis
Vaishali R. Moulton¹, Hao Li², Michael W. Mosho², Andrew R. Gillooly², Meghan L. Keane³ and George C. Tsokos⁴, ¹Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Medicine/ Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: T cells from patients with systemic lupus erythematosus (SLE) express reduced amounts of the critical CD3 zeta signaling chain, and produce low levels of…
Abstract Number: 2857 • 2016 ACR/ARHP Annual Meeting
Results from a Phase 0 Longitudinal Clinical Trial in Cutaneous Lupus Erythematosus: Analysis of the Type I IFN Signature in the Skin and Blood and Its Relationship with Disease Activity Scores and Autoantibody Profiles
Jessica Schreiter¹, Jarrat Jordan¹, Matteo Cesaroni¹, Marc Chevrier², Alexa Piantone³, Ian Gourley³, Jacqueline Benson¹ and Takahiro Sato¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research and Development, LLC, Collegeville, PA, ³Immunology Translational Medicine, Janssen Pharmaceutical Research and Development, LLC, Spring House, PA
Background/Purpose: Type I IFN (IFN-I)-regulated gene expression is known to be elevated in blood and skin lesions of patients with two different forms of cutaneous…
Abstract Number: 3191 • 2016 ACR/ARHP Annual Meeting
Coronary Revascularization Procedure Rates and Risks Among Patients with Systemic Lupus Erythematosus Compared to Those with Diabetes Mellitus in a Nationwide Medicaid Cohort
Medha Barbhaiya¹, Candace H. Feldman¹, Sarah K. Chen², Hongshu Guan³, Tzu-Chieh Lin¹, Michael A. Fischer⁴, Daniel H. Solomon⁵, Brendan M. Everett⁶ and Karen H. Costenbader¹, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose : We have recently found that myocardial infarction (MI) risk was similar among age- and sex-matched SLE patients compared to diabetes mellitus (DM) patients…
Abstract Number: 767 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Induced Retinopathy in SLE
Michelle Petri¹ and Wei Fu², ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Retinal toxicity from hydroxychloroquine (HCQ), has been recognized for many years. But poor compliance of HCQ might confound results of previous studies. Therefore, we…
Abstract Number: 1083 • 2016 ACR/ARHP Annual Meeting
Discovery and Subsequent Diagnostic Verification of Autoantibodies Against the Major Vault Protein (MVP) in Systemic Lupus Erythematosus
Petra Budde¹, Johannes Schulte-Pelkum¹, Daniel Wirtz¹, Hans-Dieter Zucht¹, Heike Göhler¹, Stefan Vordenbäumen², Peter Schulz-Knappe¹ and Matthias Schneider³, ¹Protagen AG, Dortmund, Germany, ²Rheumatology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, ³Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: In systemic lupus erythematosus (SLE), early diagnosis and prognostic stratification are still great challenges. The broad characterization of the autoantibody repertoire in SLE is…
Abstract Number: 1767 • 2016 ACR/ARHP Annual Meeting
Poor Body Image in Lupus: Is It Disease Activity, Damage, Sleep, Pain, Fatigue, Stress, Function, Medications, Depression or Fibromyalgia?
Stacy Weinberg¹, Nisarg Gandhi², Meenakshi Jolly³, Winston Sequeira² and Shilpa Arora², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³Rush, Chicago, IL
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have poorer body image (BI) than age matched controls. Few studies have been done looking at the effect…
Abstract Number: 2060 • 2016 ACR/ARHP Annual Meeting
Bim Suppresses the Development of SLE By Limiting Macrophage Inflammatory Responses
FuNien Tsai¹, Carla Cuda², Harris R. Perlman³, Philip J. Homan⁴, Salina Dominguez², Alexander Shaffer³, George Kenneth Haines III⁵ and Jack Hutcheson⁶, ¹Medicine-Rheumatology, Northwestern University-Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Chicago, IL, ³Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁴Medicine-Rheumatology, Northwestern University, Chicago, IL, ⁵Mount Sinai, New York, NY, ⁶UT Southwestern, Dallas, TX
Background/Purpose: The Bcl-2 family guards the mitochondrial apoptotic pathway. Among numerous Bcl-2 antagonists, only the loss of Bim in mice leads to the development of…
Abstract Number: 2864 • 2016 ACR/ARHP Annual Meeting
Identifying Dysregulated and Co-Dysregulated Markers in Systemic Lupus Erythematosus Using Multi-Modal Biomarker Data from a Large Pre-Clinical Study
Yanhua Sarah Hu¹, S Bandyopadhyay¹, Julie Carman², Nataly Manjarrez-Orduño², Can Jiang¹, Suzanne Suchard², Laurence Menard², sium habte¹, selena kansal¹, vivek jayaswal³, Richard A. Furie⁴ and Steven G. Nadler⁵, ¹Bristol-Myers Squibb, Princeton, NJ, ²Discovery Translational Sciences Group, Bristol-Myers Squibb, Princeton, NJ, ³Biocon Bristol-Myers Squibb Research Center, Bangalore, NJ, India, ⁴Division of Rheumatology, North Shore LIJ Health System, Great Neck, NY, ⁵Immunosciences Translational Research, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, relapsing autoimmune disease affecting multiple organs and is a highly heterogeneous condition, with wide variations in the…
Abstract Number: 3239 • 2016 ACR/ARHP Annual Meeting
Expression of IFN-Regulated Genes in Autoantibody Exposed Babies in Utero
Malin Hedlund¹, Gudny-Ella Thorlacius¹, Margarita Ivanchenko¹, Vijole Ottosson¹, Amina Ossoinak¹, Linda Lagnefeldt¹, Joanna Tingstrom¹, Alexander Espinosa¹, Lars Rönnblom², Maija-Leena Eloranta², Sven-Erik Sonesson¹ and Marie Wahren-Herlenius³, ¹Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Stockholm, Sweden, ²Uppsala University, Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala, Sweden, ³Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Ro/SSA autoantibodies and an IFN signature are commonly present in women with Sjögren’s syndrome and SLE. During pregnancy, the autoantibodies are transported across the…
Abstract Number: 769 • 2016 ACR/ARHP Annual Meeting
Response to Belimumab in SLE Patients with High Disease Activity: Data from a Multicentric Clinical-Practice Based Study Cohort
Luca Iaccarino¹, Silvano Bettio², Rossella Reggia³, Giacomo Emmi⁴, Fulvia Ceccarelli⁵, Chiara Tani⁶, Maria Gerosa⁷, Marcello Govoni⁸, Alesandra Bortoluzzi⁹, Salvatore De Vita¹⁰, Ginevra De Marchi¹¹, Rossella De Angelis¹², Andrea Di Matteo¹², Carlo Salvarani¹³, Giulia Pazzola¹³, Elena Bartoloni-Bocci¹⁴, Laura Andreoli¹⁵, Margherita Zen¹⁶, Fabrizio Conti¹⁷, Marta Mosca⁶, Pier Luigi Meroni¹⁸, Roberto Gerli¹⁴, Angela Tincani¹⁹, Andrea Doria²⁰ and Lorenzo Emmi²¹, ¹Department of Medicine-DIMED, University of Padova, Padova, Italy, ²Rheumatology Unit, Univeristy of Padova, Padova, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁴Medical Pathology, Careggi University Hospital, Firenze, Italy, ⁵Sapienza University of Rome, Rome, Italy, ⁶Rheumatology Unit, University of Pisa, Pisa, Italy, ⁷University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁸Medical Sciences, UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ⁹UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ¹⁰Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia", Udine, Italy, Udine, Italy, ¹¹Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, ¹²Polytechnic university of Marche, Rheumatologic Clinic, Iesi, Italy, ¹³Rheumatology Unit, Internal Medicine Department, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ¹⁴Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ¹⁵University of Brescia, Spedali Civili, Brescia, Italy, ¹⁶Division of Rheumatology, University of Padova, Padova, Italy, ¹⁷Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ¹⁸Rheumatology Department, University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ¹⁹Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Italy, ²⁰Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ²¹Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic,, Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic, AOU Careggi, Florence, Italy
Background/Purpose: To investigate effectiveness and identify predictors of response to belimumab in patients with active SLE in clinical practice setting. Methods: One hundred eighty eight…
Abstract Number: 1121 • 2016 ACR/ARHP Annual Meeting
IFN Regulatory Factor-5 Signaling Increases IFN-Gamma Production and Suppresses IL-2 Production from CD4+ T Cells, and Controls IgG Production in B Cells
Kei Yasuda¹, Prachi Shukla², Ramon G. Bonegio¹ and Ian Rifkin¹, ¹Renal Section, Boston Univ Schl of Med, Boston, MA, ²Boston University School of Medicine, Boston, MA
Background/Purpose: Recent studies of human genetics and mouse models have shown that interferon regulatory factor-5 (IRF5) is associated with the development of autoimmune disease. However,…
Abstract Number: 1768 • 2016 ACR/ARHP Annual Meeting
Fatigue in SLE Is Associated with Neuropsychiatric Involvement, Pain, Impaired Sleep and a Reduced Quality of Life
Andreas Jönsen¹, Pia C Sundgren², Jessika Nystedt³, Petra Nilsson³, Åsa Lilja⁴ and Anders A. Bengtsson¹, ¹Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden, ²Department of Diagnostic Radiology, Lund University, Lund, Sweden, ³Department of Clinical Sciences, Neurology, Lund University, Lund, Sweden, ⁴Center for Primary Health Care Research, Lund University, Malmö, Sweden
Background/Purpose: Fatigue is a major patient complaint in SLE, often severely impacting quality of life and activities including work. In this study, we analyze neuropsychiatric…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].